Search our Database of Scientific Publications and Authors

I’m looking for a
    Improvement in quality of life by using duloxetine for chemotherapy-induced peripheral neuropathy (CIPN): a case report.
    Support Care Cancer 2016 Nov 23;24(11):4483-5. Epub 2016 Jul 23.
    Department of Radiation Oncology, University of Tokyo Hospital, 7-3-1, Bunkyo-ku, Hongo, 113-8655, Tokyo, Japan.

    Similar Publications

    Serotonin-norepinephrine reuptake inhibitors for the management of chemotherapy-induced peripheral neuropathy.
    Ann Pharmacother 2014 May 27;48(5):626-32. Epub 2014 Feb 27.
    Virginia Commonwealth University Health System/Medical College of Virginia Hospitals, Richmond, VA, USA.
    Objective: To review the literature evaluating serotonin-norepinephrine reuptake inhibitors (SNRIs) for chemotherapy-induced peripheral neuropathy (CIPN).

    Data Sources: A PubMed search (1966-January 2014) was performed using the key terms serotonin-norepinephrine reuptake inhibitor, desvenlafaxine, duloxetine, milnacipran, venlafaxine, chemotherapy, and peripheral neuropathy. Bibliographies of select articles were examined for additional references and abstracts. Read More
    Predictors of the usefulness of duloxetine for chemotherapy-induced peripheral neuropathy.
    Med Oncol 2017 Aug 7;34(8):137. Epub 2017 Jul 7.
    Departments of Pain Treatment and Palliative Care Unit, University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan.
    Duloxetine is an effective therapeutic agent for chemotherapy-induced peripheral neuropathy (CIPN). However, predictors of duloxetine response have not been adequately explored. Therefore, this retrospective study was performed to identify predictive factors of duloxetine response in CIPN patients to guide future strategies to improve the quality of life of patients undergoing chemotherapy. Read More
    Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial.
    Int J Clin Oncol 2015 Oct 12;20(5):866-71. Epub 2015 Mar 12.
    Department of Medical Oncology/Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan.
    Background: Chemotherapy-induced peripheral neuropathy (CIPN) is difficult to manage. A phase III trial conducted in the United States demonstrated that duloxetine was effective for CIPN caused by taxane and platinum-based chemotherapy. No randomized trial of duloxetine for CIPN has been conducted in Japan. Read More
    Prevention and treatment of chemotherapy-induced peripheral neuropathy.
    Am J Health Syst Pharm 2014 Jan;71(1):19-25
    Jennifer Piccolo, Pharm.D., is Clinical Oncology Pharmacist, Froedert and The Medical College of Wisconsin, Milwaukee. Jill M. Kolesar, Pharm.D., BCPS, FCCP, is Professor of Pharmacy, School of Pharmacy, University of Wisconsin-Madison, and Director, 3P Analytical Laboratory, University of Wisconsin Carbone Comprehensive Cancer Center, Madison.
    Purpose: The prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN) are reviewed.

    Summary: A number of agents, including amifostine, glutathione, and vitamin E, were evaluated as prevention strategies for CIPN, with no agent demonstrating efficacy. Calcium and magnesium are effective for the prevention of CIPN; however, concerns regarding reduced chemotherapy efficacy linger. Read More